You are here

Revised Labeling for Aranesp, Epogen, and Procrit Provides Updated Safety Information About Pure Red Cell Aplasia and Severe Anemia

December 1, 2005 -- ROCKVILLE, MD -- Amgen, Ortho Biotech and FDA notified healthcare professionals of revision to the Warnings, Precautions, Adverse Reactions, and Dosage and Administration sections of the prescribing information for these three products. The revised labeling provides updated safety information on reports of pure red cell aplasia and severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin in patients treated with these products. This has been reported predominantly in patients with CRF receiving these products by subcutaneous administration. Recommendations for evaluation and treatment are provided in the new prescribing information.

Read the complete MedWatch 2005 Safety summary, including links to the Dear Healthcare Professional letters and revised prescribing information at:


Source: The Food and Drug Administration

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring